Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PAK1 | Q13153 | 6/20 | 0.58 |
| ▸ | PAK4 | O96013 | 5/20 | 0.58 |
| ▸ | AURKA | O14965 | 1/20 | 0.58 |
| ▸ | IGF1R | P08069 | 4/20 | 0.56 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.53 |
| ▸ | PAK3 | O75914 | 1/20 | 0.52 |
| ▸ | PAK2 | Q13177 | 1/20 | 0.52 |
| ▸ | CCNK | O75909 | 1/20 | 0.50 |
| ▸ | CDK13 | Q14004 | 1/20 | 0.50 |
| ▸ | CDK12 | Q9NYV4 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26049061 | 0.89 | PAK1 (0.57) | PAK1PAK4AURKAIGF1RNEK1 | |
| SCHEMBL25370237 | 0.88 | PAK1 (0.54) | PAK1PAK4AURKAIGF1RNEK1 | |
| SCHEMBL26050905 | 0.88 | PAK1 (0.53) | PAK1PAK4AURKAIGF1RNEK1 | |
| SCHEMBL26052098 | 0.86 | PAK1 (0.56) | PAK1PAK4AURKAIGF1RPAK3 | |
| SCHEMBL30566830 | 0.83 | PAK1 (0.49) | PAK1PAK4AURKAIGF1RPAK3 | |
| SCHEMBL25370665 | 0.83 | PAK1 (0.49) | PAK1PAK4AURKAIGF1RPAK3 | |
| SCHEMBL25371017 | 0.83 | IGF1R (0.68) | PAK1PAK4IGF1RNEK1CCNK | |
| SCHEMBL30558769 | 0.83 | IGF1R (0.68) | PAK1PAK4IGF1RNEK1CCNK | |
| SCHEMBL26050488 | 0.81 | IGF1R (0.54) | PAK1PAK4AURKAIGF1RPAK3 | |
| SCHEMBL26576013 | 0.79 | PAK1 (0.63) | PAK1PAK4AURKAIGF1RNEK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250170130-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2025-05-29 | — | — | US | disclosed |
| WO-2023164611-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-08-31 | — | — | WO | disclosed |
| WO-2023164611-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | NALO THERAPEUTICS (US) | 2023-08-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20250170130-A1 | MODULATORS OF MYC FAMILY PROTO-ONCOGENE PROTEIN | MYC, MYCBP, MYCBP2 | PAK1 222/4885PAK4 528/4885AURKA 1845/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.